

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Endocrine/metabolic disease</b>				
Diabetes	Fatty acid binding protein 4 adipocyte (FABP4)	<i>In vitro</i> and mouse studies suggest blocking FABP4 could help treat diabetes. In primary hepatocytes and in lean mice, recombinant Fabp4 stimulated glucose production and gluconeogenesis. In obese mice, secretion of Fabp4 from adipocytes was greater than that in lean mice, and a neutralizing FABP4-targeting antibody decreased Fabp4 serum levels and increased glucose metabolism and clearance compared with a control antibody. Next steps include developing a humanized mAb targeting FABP4.	Patent application filed for the use of antibodies targeting FABP4 in diabetes; exclusively licensed to UCB Group	Cao, H. <i>et al. Cell Metab.</i> ; published online May 7, 2013; doi:10.1016/j.cmet.2013.04.012 <b>Contact:</b> Gökhan S. Hotamisligil, Harvard School of Public Health, Boston, Mass. e-mail: <a href="mailto:gshotamis@hsph.harvard.edu">gshotamis@hsph.harvard.edu</a>
		<b>SciBX 6(22); doi:10.1038/scibx.2013.547</b> Published online June 6, 2013		